Welcome to our dedicated page for Aurinia Pharmace news (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmace stock.
Aurinia Pharmaceuticals Inc. reports news centered on its autoimmune-disease biopharmaceutical business, led by LUPKYNIS (voclosporin), an FDA-approved oral therapy for adult patients with active lupus nephritis. Recurring updates cover product sales, total revenue, license, collaboration and royalty revenue, and business progress tied to commercialization of LUPKYNIS.
Company news also includes pipeline development for aritinercept, a dual BAFF and APRIL inhibitor being developed for autoimmune diseases, as well as collaboration activity with Otsuka, financial guidance, share repurchase activity, executive appointments, board matters and shareholder governance commentary.
Aurinia (NASDAQ: AUPH) reached a settlement with Teva resolving U.S. patent litigation over Teva’s proposed generic 7.9 mg voclosporin capsules. Teva stipulated that Aurinia’s U.S. Patents 10,286,036 and 11,622,991, expiring in December 2037, are enforceable, valid and would be infringed by commercial U.S. sales of its generic product.
The agreement allows Teva to launch its generic voclosporin in the United States no earlier than December 7, 2036, subject to FDA approval and certain contingencies. Aurinia noted that its separate patent infringement actions against several other generic companies remain ongoing in the U.S. District Court for the District of New Jersey.
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported Q2 2026 total revenue of $83.2 million, up 19% year over year, and six‑month revenue of $160.9 million, up 21%. Net product sales of LUPKYNIS were $79.4 million in Q2 and $153.0 million year to date, both up 19% and 21%, respectively.
Net income rose to $37.4 million in Q2 and $71.8 million for six months, increases of 74% and 60%. Diluted EPS was $0.28 for Q2 and $0.53 year to date. Operating cash flow reached $52.5 million in Q2 and $85.1 million for six months. Cash, cash equivalents, restricted cash and investments totaled $443.1 million at June 30, 2026, after repurchasing 5.0 million shares for $74.9 million. Aurinia reiterated 2026 total revenue guidance of $315–$325 million and LUPKYNIS net product sales guidance of $305–$315 million. The company also initiated the Phase 4 PRESERVE study in lupus nephritis and advanced aritinercept into four autoimmune indications.
Aurinia (NASDAQ:AUPH) initiated PRESERVE, a Phase 4, multicenter study in lupus nephritis evaluating LUPKYNIS® combined with belimumab, obinutuzumab or anifrolumab.
The US trial plans to enroll about 150 patients at ~50 sites, with primary endpoint of complete renal response at 6 months, targeting faster proteinuria control via a multitarget mechanism.
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported new AURORA 1 Phase 3 data for LUPKYNIS in lupus nephritis at EULAR 2026. In 356 patients, LUPKYNIS was associated with a 53% reduction in risk of renal-related event or death (hazard ratio 0.47; p=0.0007).
Hazard ratios also favored LUPKYNIS for death (HR 0.19; p=0.0929), treatment failure (HR 0.45; p=0.0062) and worsening proteinuria (HR 0.22; p<0.0001). An investigator noted LUPKYNIS previously showed statistically significant complete renal response at 6 months in Phase 3.
Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 2026 results: total revenue $77.7M (+24% YoY) and net product sales $73.6M (+23% YoY). Q1 net income was $34.4M (+48%) and diluted EPS was $0.25 (+56%). Cash, cash equivalents and investments totaled $378.8M at March 31, 2026. The company reiterated 2026 guidance of $315M–$325M total revenue and $305M–$315M net product sales, representing an 11%–16% increase versus 2025.
Aurinia Pharmaceuticals (NASDAQ:AUPH) agreed to acquire Kezar Life Sciences (NASDAQ:KZR) for $6.955 cash per share plus one non-transferable contingent value right (CVR) tied to zetomipzomib development, certain collaboration/sale proceeds, and >100% of Kezar closing net cash above $50 million.
The tender offer will commence by April 13, 2026; closing is conditioned on majority tender, Kezar closing net cash exceeding $50 million net of CVR-related expenses, and customary conditions, with completion expected in Q2 2026.
MKT Capital, a long-term shareholder, praised Aurinia Pharmaceuticals (NASDAQ: AUPH) leadership changes after the Board removed CEO Peter Greenleaf and appointed Kevin Tang as CEO effective March 23, 2026. Key actions include CEO zero compensation, a $150 million share repurchase, discontinuing non-core R&D saving >$50 million annually, Board reduction from nine to six, and replacing time-based RSUs with performance awards.
MKT Capital says these moves conclude multi-year activist efforts and aim to prioritize disciplined capital allocation, shareholder alignment, and commercial execution for LUPKYNIS and AUR200.
Aurinia (NASDAQ: AUPH) announced a leadership transition on March 23, 2026: Kevin Tang, chair of the board, will succeed Peter Greenleaf as CEO, and Greenleaf will remain as a consultant to support the handover. The company named Ryan Cole as COO, Michael Hearne as CFO and Thomas Wei as CSO.
The announcement highlights LUPKYNIS as emerging therapy for lupus nephritis and notes that lead pipeline candidate aritinercept is advancing through clinical studies. Stew Kroll and Stephen Robertson remain as chief development officer and general counsel.
Aurinia Pharmaceuticals (NASDAQ: AUPH) reported 2025 results: total revenue $283.1M (+20%) and LUPKYNIS net product sales $271.3M (+25%). Net income was $287.2M driven by a $173.0M income tax benefit from releasing a valuation allowance. Cash and investments were $398.0M; the company repurchased 12.2M shares for $98.2M. For 2026 Aurinia guides total revenue $315M–$325M and LUPKYNIS sales $305M–$315M. The company plans additional clinical starts for aritinercept in H1 2026.
Aurinia Pharmaceuticals (NASDAQ: AUPH) will report financial results for the three and twelve months ended December 31, 2025, and provide a business update on February 26, 2026.
Management will host a webcast and conference call on February 26, 2026 at 8:30 a.m. ET; call dial-ins and a replay will be available on the company website.